JP2007512381A - 医薬的組み合わせ - Google Patents

医薬的組み合わせ Download PDF

Info

Publication number
JP2007512381A
JP2007512381A JP2006541869A JP2006541869A JP2007512381A JP 2007512381 A JP2007512381 A JP 2007512381A JP 2006541869 A JP2006541869 A JP 2006541869A JP 2006541869 A JP2006541869 A JP 2006541869A JP 2007512381 A JP2007512381 A JP 2007512381A
Authority
JP
Japan
Prior art keywords
arthritis
combination
rheumatoid arthritis
treatment
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006541869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007512381A5 (cg-RX-API-DMAC10.html
Inventor
アクセル・マイビューヒャー
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2007512381A publication Critical patent/JP2007512381A/ja
Publication of JP2007512381A5 publication Critical patent/JP2007512381A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2006541869A 2003-12-01 2004-11-30 医薬的組み合わせ Pending JP2007512381A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0327840.5A GB0327840D0 (en) 2003-12-01 2003-12-01 Organic compounds
PCT/EP2004/013587 WO2005053661A2 (en) 2003-12-01 2004-11-30 Pharmaceutical combinations

Publications (2)

Publication Number Publication Date
JP2007512381A true JP2007512381A (ja) 2007-05-17
JP2007512381A5 JP2007512381A5 (cg-RX-API-DMAC10.html) 2008-01-24

Family

ID=29798110

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006541869A Pending JP2007512381A (ja) 2003-12-01 2004-11-30 医薬的組み合わせ

Country Status (11)

Country Link
US (1) US20070117833A1 (cg-RX-API-DMAC10.html)
EP (1) EP1819361A2 (cg-RX-API-DMAC10.html)
JP (1) JP2007512381A (cg-RX-API-DMAC10.html)
KR (1) KR20060122877A (cg-RX-API-DMAC10.html)
CN (1) CN1886157A (cg-RX-API-DMAC10.html)
AU (1) AU2004294282B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0417146A (cg-RX-API-DMAC10.html)
CA (1) CA2546738A1 (cg-RX-API-DMAC10.html)
GB (1) GB0327840D0 (cg-RX-API-DMAC10.html)
RU (1) RU2006123312A (cg-RX-API-DMAC10.html)
WO (1) WO2005053661A2 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
WO2006053754A1 (en) * 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
AU2006315512B2 (en) * 2005-11-14 2012-11-01 Ariad Pharmaceuticals, Inc. Administration of an mTOR inhibitor to treat patients with cancer
EP1880723A1 (en) * 2006-07-14 2008-01-23 Novartis AG Combination of mTOR inhibitor and antifolate compound
JP2009523149A (ja) * 2006-01-12 2009-06-18 ノバルティス アクチエンゲゼルシャフト ｍＴＯＲ阻害剤および抗葉酸化合物の組み合わせ
KR20140016439A (ko) * 2006-02-02 2014-02-07 노파르티스 아게 결절성 경화증의 치료
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
CA2669415A1 (en) 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08502266A (ja) * 1992-10-09 1996-03-12 サンド・リミテッド Ｏ−アルキル化ラパマイシン誘導体および、特に免疫抑制剤としてのその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
DE69624921T2 (de) * 1995-06-09 2003-09-11 Novartis Ag, Basel Rapamycinderivate
GB0123025D0 (en) * 2001-09-25 2001-11-14 Eirx Therapeutics Ltd Apoptosis
JP2005514411A (ja) * 2002-01-10 2005-05-19 ノバルティス アクチエンゲゼルシャフト ラパマイシンおよびその誘導体を含む血管疾患の予防および処置用薬剤送達システム
EP1478648B1 (en) * 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
WO2003106622A2 (en) * 2002-05-30 2003-12-24 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
TW200902047A (en) * 2003-02-14 2009-01-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08502266A (ja) * 1992-10-09 1996-03-12 サンド・リミテッド Ｏ−アルキル化ラパマイシン誘導体および、特に免疫抑制剤としてのその使用

Also Published As

Publication number Publication date
GB0327840D0 (en) 2003-12-31
AU2004294282B2 (en) 2009-05-07
BRPI0417146A (pt) 2007-03-06
CN1886157A (zh) 2006-12-27
EP1819361A2 (en) 2007-08-22
RU2006123312A (ru) 2008-01-20
WO2005053661A3 (en) 2005-12-29
US20070117833A1 (en) 2007-05-24
CA2546738A1 (en) 2005-06-16
AU2004294282A1 (en) 2005-06-16
WO2005053661A2 (en) 2005-06-16
KR20060122877A (ko) 2006-11-30

Similar Documents

Publication Publication Date Title
Johnston et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
US8119649B2 (en) Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
JP5902141B2 (ja) 脂質キナーゼおよびｍＴＯＲのデュアル阻害剤としてのイミダゾキノリン
US20120128665A1 (en) Preselection of subjects for therapeutic treatment based on hypoxic status
JP2020105181A (ja) 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法
CA2998509A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
MX2008014365A (es) Metodos para tratar enfermedades autoinmunitarias utilizando una molecula de fusion del activador de transmembrana-inmunoglobulina.
MXPA04003266A (es) Combinaciones para el tratamiento de desodrdenes inmuno-inflamatorios.
Nakashima et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate
CN109069467B (zh) 肌生成抑制蛋白拮抗剂的用途、含有它们的组合及其用途
KR20220163986A (ko) 브루톤 티로신 키나아제의 억제제를 이용한 재발성 다발성 경화증의 치료 방법
AU2004294282B2 (en) Pharmaceutical combinations
KR20080100484A (ko) 류마티스관절염 치료용 ｖｘ-702의 용도
KR20220148826A (ko) 브루톤 티로신 키나아제의 저해제를 이용하여 원발성 진행형 다발성 경화증을 치료하는 방법
EP3068491B1 (en) 7-aminocephalosporanic acid derivative as inhibitor of il-15 and il-2 activity
CN114144229A (zh) 心血管功能障碍的性别依赖性治疗方法和材料
MXPA06006220A (en) Pharmaceutical combinations
WO2014191822A1 (en) BENZOIC ACID DERIVATIVES AS IL-15Rα RECEPTOR INHIBITORS
CN101677978B (zh) 矫正骨吸收和骨形成失调的方法及其试剂盒和组合物
Beck et al. Oral agents for psoriasis
HK40031991B (en) Methods of treating and preventing graft versus host disease
Avdeeva et al. THU0110 The Effect of Subcutaneous (SC) Methotrexate (MTX) and Adalimumab (ADA) on Cytokine Profile in MTX-Naive Patients with Early Rheumatoid Arthritis (RA)
Nakamura Therapeutic Strategies in Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis
Gittoes Therapeutic progress I: Current treatment of rheumatoid arthritis
HK1128426A (en) Methods for treating autoimmune diseases using a taci-ig fusion molecule

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101012

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110308